<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (aPLs) have been implicated in atherogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>We studied 344 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes; approximately 40% were aPL+ in 1 or more tests and 60% aPL- </plain></SENT>
<SENT sid="2" pm="."><plain>In 215 patients, <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) was angiographically documented, with 43.7% positive for aPL vs 34.9% of patients without CAD positive for aPLs </plain></SENT>
<SENT sid="3" pm="."><plain>Anti-beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta2GPI; 54%) and anti-oxidized <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (oxLDL)/beta2GPI (48%) were most frequent, accounting for 87% of <z:hpo ids='HP_0000001'>all</z:hpo> aPL+ CAD cases </plain></SENT>
<SENT sid="4" pm="."><plain>aPLs correlated with severity of CAD (P = .012) </plain></SENT>
<SENT sid="5" pm="."><plain>Adverse events occurred in 16.7% of patients with CAD, more frequently in patients who were aPL+ (P = .0006; relative risk, 2.9; 95% confidence interval, 1.5-5.6) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients who were aPL+ with severe CAD had more adverse events than patients who were aPL- with severe CAD (P = .005) and aPL+ patients undergoing revascularization procedures (P = .001) </plain></SENT>
<SENT sid="7" pm="."><plain>Vascular events occurred in 21.7% of aPL+ patients compared with 7.1% of aPL- patients (P = .005) </plain></SENT>
<SENT sid="8" pm="."><plain>Anti-beta2GPI and anti-oxLDL/beta2GPI were associated with CAD severity and adverse outcomes </plain></SENT>
</text></document>